Literature DB >> 15527080

Surgical resection for patients with benign primary brain tumors and low grade gliomas.

Joseph Piepmeier1, Joachim M Baehring.   

Abstract

'Benign' brain tumors are a heterogeneous group of primary neoplasms representing 40% of primary brain tumors. Amongst neuroepithelial tumors, astrocytic neoplasms predominate, followed by oligodendroglial and mixed glial and glial-neuronal neoplasms. Less common are tumors of the ependyma, choroid plexus and neuroepithelial tumors of unknown origin such as chordoid glioma of the third ventricle. Neurosurgical intervention is indicated in order to establish a diagnosis, alleviate symptoms of mass effect, hydrocephalus, or hemorrhage, remove a seizure focus and decrease the cell pool at risk of malignant degeneration. As the majority of patients survive their tumor for years after initial diagnosis, the benefits of therapy must be carefully weighed against adverse treatment effects. This article, with a particular focus on surgical management, reflects the authors approach to the treatment of low-grade tumors of the brain parenchyma in the adult and reviews the pertinent literature published on this controversial issue.

Entities:  

Mesh:

Year:  2004        PMID: 15527080     DOI: 10.1023/b:neon.0000041871.46785.53

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  51 in total

1.  Pleomorphic xanthoastrocytoma: what do we really know about it?

Authors:  C Giannini; B W Scheithauer; P C Burger; D J Brat; P C Wollan; B Lach; B P O'Neill
Journal:  Cancer       Date:  1999-05-01       Impact factor: 6.860

Review 2.  Oligodendroglioma: an appraisal of recent data pertaining to diagnosis and treatment.

Authors:  D Fortin; G J Cairncross; R R Hammond
Journal:  Neurosurgery       Date:  1999-12       Impact factor: 4.654

3.  Third ventricular chordoid glioma: a distinct clinicopathologic entity.

Authors:  D J Brat; B W Scheithauer; S M Staugaitis; S C Cortez; K Brecher; P C Burger
Journal:  J Neuropathol Exp Neurol       Date:  1998-03       Impact factor: 3.685

4.  Dysembryoplastic neuroepithelial tumors: nonspecific histological forms -- a study of 40 cases.

Authors:  C Daumas-Duport; P Varlet; S Bacha; F Beuvon; P Cervera-Pierot; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1999-02       Impact factor: 4.130

5.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria.

Authors:  C Daumas-Duport; M L Tucker; H Kolles; P Cervera; F Beuvon; P Varlet; N Udo; M Koziak; J P Chodkiewicz
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

6.  Patterns of tumor progression after radiotherapy for low-grade gliomas: analysis from the computed tomography/magnetic resonance imaging era.

Authors:  S Rudoler; B W Corn; M Werner-Wasik; A Flanders; P E Preston; L Tupchong; W J Curran
Journal:  Am J Clin Oncol       Date:  1998-02       Impact factor: 2.339

Review 7.  Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature.

Authors:  C M Dirven; J J Mooij; W M Molenaar
Journal:  Childs Nerv Syst       Date:  1997-01       Impact factor: 1.475

8.  The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects.

Authors:  Cordelia Luyken; Ingmar Blümcke; Rolf Fimmers; Horst Urbach; Christian E Elger; Otmar D Wiestler; Johannes Schramm
Journal:  Epilepsia       Date:  2003-06       Impact factor: 5.864

Review 9.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

10.  Dysembryoplastic neuroepithelial tumor: a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases.

Authors:  C Daumas-Duport; B W Scheithauer; J P Chodkiewicz; E R Laws; C Vedrenne
Journal:  Neurosurgery       Date:  1988-11       Impact factor: 4.654

View more
  11 in total

1.  Retrospective protein expression and epigenetic inactivation studies of CDH1 in patients affected by low-grade glioma.

Authors:  Pietro Ivo D'Urso; Oscar Fernando D'Urso; Carlo Storelli; Giuseppe Catapano; Cosimo Damiano Gianfreda; Antonio Montinaro; Antonella Muscella; Santo Marsigliante
Journal:  J Neurooncol       Date:  2010-12-03       Impact factor: 4.130

2.  Extent of resection and survival for oligodendroglioma: a U.S. population-based study.

Authors:  Connor J Kinslow; Andrew L A Garton; Ali I Rae; Logan P Marcus; Christopher M Adams; Guy M McKhann; Michael B Sisti; E Sander Connolly; Jeffrey N Bruce; Alfred I Neugut; Adam M Sonabend; Peter Canoll; Simon K Cheng; Tony J C Wang
Journal:  J Neurooncol       Date:  2019-08-12       Impact factor: 4.130

Review 3.  Benefits of dynamic susceptibility-weighted contrast-enhanced perfusion MRI for glioma diagnosis and therapy.

Authors:  Ramon Francisco Barajas; Soonmee Cha
Journal:  CNS Oncol       Date:  2014-11

4.  Early or delayed radiosurgery for WHO grade II astrocytomas.

Authors:  Kyung-Jae Park; Hideyuki Kano; Douglas Kondziolka; Ajay Niranjan; John C Flickinger; L Dade Lunsford
Journal:  J Neurooncol       Date:  2010-09-17       Impact factor: 4.130

Review 5.  New concepts in surgery of WHO grade II gliomas: functional brain mapping, connectionism and plasticity--a review.

Authors:  Hugues Duffau
Journal:  J Neurooncol       Date:  2006-04-11       Impact factor: 4.130

6.  Prediction of malignancy grading using computed tomography perfusion imaging in nonenhancing supratentorial gliomas.

Authors:  Takaaki Beppu; Makoto Sasaki; Kohsuke Kudo; Akira Kurose; Masaru Takeda; Hiroshi Kashimura; Akira Ogawa; Kuniaki Ogasawara
Journal:  J Neurooncol       Date:  2010-10-15       Impact factor: 4.130

7.  Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas.

Authors:  Tareq A Juratli; Mirko Peitzsch; Kathrin Geiger; Gabriele Schackert; Graeme Eisenhofer; Dietmar Krex
Journal:  Neuro Oncol       Date:  2013-02-14       Impact factor: 13.029

8.  Long-Term Results of stereotactic Brachytherapy (Temporary 125Iodine Seeds) for the Treatment of Low-Grade Astrocytoma (Grade II).

Authors:  Sohrab Shahzadi; Parisa Azimi; Khosrow Parsa
Journal:  Iran Red Crescent Med J       Date:  2013-01-05       Impact factor: 0.611

9.  Analysis of MRI Volumetric Changes After Hypofractionated Stereotactic Radiation Therapy for Benign Intracranial Neoplasms.

Authors:  Kathryn R Fega; Geoffrey P Fletcher; Mark R Waddle; Jennifer L Peterson; Jonathan B Ashman; David M Barrs; Bernard R Bendok; Naresh P Patel; Alyx B Porter; Sujay A Vora
Journal:  Adv Radiat Oncol       Date:  2018-08-23

10.  Glioma SOX2 expression decreased after adjuvant therapy.

Authors:  Wei Yu; Xiaoqiu Ren; Chunxiu Hu; Yinuo Tan; Yongjie Shui; Zexin Chen; Lili Zhang; Jiaping Peng; Qichun Wei
Journal:  BMC Cancer       Date:  2019-11-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.